Visceral Adipose Tissue (VAT): How to Interpret Your Result

What Is Visceral Adipose Tissue?

Visceral adipose tissue is a distinct fat depot located inside the peritoneal cavity, behind the abdominal wall muscles. It is not the fat you can pinch. VAT surrounds the liver, kidneys, pancreas, and gut, and it behaves differently from subcutaneous adipose tissue at nearly every biological level.

VAT cells are larger, turn over faster, and are far more lipolytically active than subcutaneous fat cells. They drain directly into the portal vein, flooding the liver with free fatty acids and inflammatory mediators. The result is hepatic insulin resistance, elevated triglycerides, reduced HDL cholesterol, and a pro-inflammatory state that accelerates atherosclerosis. The Endocrine Society's 2012 scientific statement on abdominal obesity describes this portal delivery of lipid metabolites as a central mechanism linking visceral fat accumulation to cardiometabolic disease [1].

How VAT Differs from Subcutaneous Fat

Subcutaneous fat (the fat under the skin) acts partly as an energy buffer and secretes the insulin-sensitizing hormone adiponectin. VAT, by contrast, secretes higher concentrations of interleukin-6, tumor necrosis factor-alpha, resistin, and plasminogen activator inhibitor-1. Each of these promotes systemic inflammation and clotting risk.

A 2012 study in the Journal of the American College of Cardiology (N=6,809) found that VAT area, not subcutaneous fat area, predicted incident cardiovascular events after controlling for traditional risk factors [2]. Subcutaneous fat showed no independent association with events in that cohort.

Why BMI Does Not Capture VAT

Body mass index divides weight by height squared. Two people with a BMI of 27 kg/m² can differ by 2 to 3 kg of visceral fat depending on age, sex, ethnicity, and fitness history. A 2020 analysis published in JAMA Network Open showed that up to 30% of adults classified as "normal weight" by BMI carried high-risk visceral fat burdens detectable on CT or DEXA [3].

Waist circumference adds meaningful information. The AACE 2016 obesity guidelines cite sex-specific waist circumference thresholds (men >102 cm, women >88 cm for non-Asian adults) as a proxy for elevated visceral adiposity, though these thresholds are population-specific [4].

How Is VAT Measured?

CT Scan: The Reference Standard

Computed tomography at the L4-L5 vertebral level remains the most accurate single-slice method for quantifying VAT area in square centimeters. A single abdominal CT slice at L4-L5 correlates strongly (r > 0.90) with whole-abdomen VAT volume on full-body CT [5]. The tradeoff is radiation exposure (approximately 2 to 5 mSv per scan), making serial CT monitoring impractical for most outpatients.

DEXA: The Clinical Standard for Monitoring

Dual-energy X-ray absorptiometry separates the android trunk region into VAT and subcutaneous AT using a validated algorithm (GE Healthcare's CoreScan, Hologic's Android VAT). DEXA delivers roughly 0.001 to 0.003 mSv per scan, about one-tenth the radiation of a standard chest X-ray. A 2011 validation study in Obesity (N=150) found that DEXA-derived VAT mass correlated with CT-derived VAT area at r = 0.80 to 0.85 across sex and BMI categories [6].

Your lab report from a DEXA scan typically reports VAT as mass in grams or kilograms, VAT area in square centimeters, or sometimes a VAT/SAT ratio.

MRI

Magnetic resonance imaging can quantify VAT without ionizing radiation and with accuracy comparable to CT. Cost and scanner availability limit routine MRI use for body composition outside of research settings.

Normal VAT Range: What the Numbers Mean

Low-Risk: VAT Area <100 cm²

A VAT area below 100 cm² is associated with a low prevalence of insulin resistance and metabolic syndrome across multiple cohorts. The Framingham Heart Study offspring cohort (N=3,001) found that VAT area below 100 cm² corresponded to a less than 5% prevalence of metabolic syndrome [7].

On DEXA, this translates roughly to a VAT mass below 1.0 kg (1,000 g), though the exact conversion varies by machine and algorithm.

Intermediate Risk: VAT Area 100 to 160 cm²

In this zone, insulin resistance becomes measurable. Fasting triglycerides start to climb, HDL cholesterol falls, and blood pressure rises relative to individuals with VAT below 100 cm². The Women's Health Study demonstrated that participants whose VAT crossed 100 cm² had a 2.3-fold increase in type 2 diabetes incidence over 10 years compared with women below that threshold [8].

High Risk: VAT Area >160 cm²

VAT above 160 cm² is the threshold most consistently associated with cardiovascular events, non-alcoholic fatty liver disease (now termed MASLD), and sleep apnea in prospective data. A 2019 meta-analysis in Diabetes Care (23 studies, N=11,462) reported that each 10 cm² increment in CT-derived VAT area above 160 cm² was associated with an 8% increase in major adverse cardiovascular events (hazard ratio 1.08, 95% CI 1.05 to 1.11) [9].

Sex-Specific Considerations

Women accumulate VAT more slowly than men before menopause, partly because estrogen promotes gluteofemoral (hip and thigh) fat storage. After menopause, estrogen decline accelerates VAT deposition. The Endocrine Society 2019 postmenopausal hormone therapy position statement notes that estradiol therapy attenuates VAT gain in recently menopausal women [10].

For men, testosterone deficiency correlates with VAT accumulation. Testosterone replacement in hypogonadal men (total testosterone <300 ng/dL) reduces VAT area by a mean of 14.5 cm² over 12 months according to a 2016 Cochrane review [11].

VAT Risk Framework (DEXA-Based)

| VAT Area (CT) | Approx. DEXA Mass | Risk Category | Key Metabolic Associations | |---|---|---|---| | <100 cm² | <1.0 kg | Low | Minimal cardiometabolic risk in most cohorts | | 100 to 160 cm² | 1.0 to 1.6 kg | Intermediate | Insulin resistance, dyslipidemia, early hypertension | | >160 cm² | >1.6 kg | High | T2D, MASLD, CVD events, sleep apnea |

What a High VAT Result Means Clinically

A VAT result in the intermediate or high range is a direct metabolic risk signal, not merely an aesthetic concern. High VAT predicts cardiometabolic disease independent of BMI, total body fat percentage, and waist circumference.

Downstream Lab Abnormalities to Expect

Elevated VAT is frequently accompanied by a cluster of laboratory findings. Fasting triglycerides above 150 mg/dL, HDL cholesterol below 40 mg/dL in men or 50 mg/dL in women, fasting glucose between 100 to 125 mg/dL (prediabetes range), and elevated high-sensitivity CRP above 2 mg/L are each common in adults with VAT above 160 cm². The ADA Standards of Diabetes Care 2024 recommends annual hemoglobin A1c or fasting glucose screening for any adult with abdominal obesity, defined by waist circumference or body composition [12].

Liver and Cardiovascular Risk

Excess free fatty acids draining through the portal vein to the liver promote hepatic steatosis. MASLD (metabolic dysfunction-associated steatotic liver disease) affects an estimated 38% of adults globally, and VAT excess is its primary driver, as noted in a 2023 Lancet Gastroenterology review [13]. Screening liver enzymes (ALT, AST) and a FIB-4 score are reasonable first steps when VAT is high.

How to Lower Visceral Adipose Tissue

Aerobic Exercise

Aerobic training is the most consistently effective lifestyle strategy for reducing VAT. A 2021 meta-analysis in Obesity Reviews (39 randomized controlled trials, N=2,234) found that aerobic exercise reduced VAT area by a mean of 27.9 cm² compared to control groups, independent of changes in total body weight [14]. The minimum effective dose appeared to be 150 minutes per week of moderate-intensity activity (roughly 65 to 75% of maximum heart rate).

Running, cycling, rowing, and brisk walking all produce similar reductions when total energy expenditure is equated.

Resistance Training

Resistance training alone reduces VAT less than aerobic exercise but provides additive benefit when combined. A 2012 study in the American Journal of Cardiology (N=196) showed that men randomized to combined aerobic plus resistance training for 8 months lost significantly more VAT than those doing either modality alone (P<0.001 for the combined vs. Aerobic-only group) [15].

Dietary Strategies

Caloric restriction reduces VAT proportionally more than subcutaneous fat. In the CALERIE trial (N=218), a 25% caloric restriction diet over 2 years produced a 27% reduction in VAT volume measured by MRI, compared to a 6% reduction in subcutaneous fat [16]. Low-glycemic and Mediterranean dietary patterns show comparable VAT reductions to low-fat diets when calories are matched.

Reducing ultra-processed foods and refined carbohydrates specifically targets the hepatic lipogenesis pathway most directly linked to VAT expansion.

GLP-1 Receptor Agonists

Semaglutide 2.4 mg (Wegovy) is the most extensively studied pharmacologic agent for VAT reduction. In STEP-1 (N=1,961), participants receiving semaglutide 2.4 mg subcutaneously once weekly for 68 weeks lost 14.9% of body weight versus 2.4% with placebo (P<0.001) [17]. A substudy using DEXA measured VAT mass: the semaglutide group lost approximately 30% of baseline VAT mass, roughly triple the reduction in total body weight percentage.

Tirzepatide (Mounjaro/Zepbound), a dual GIP/GLP-1 receptor agonist, showed even greater body composition effects. In SURMOUNT-1 (N=2,539), the 15 mg dose produced a mean 22.5% body weight reduction at 72 weeks [18]. DEXA substudies confirmed disproportionate VAT reduction.

Liraglutide 3.0 mg (Saxenda) produced a 16% reduction in VAT area versus placebo over 56 weeks in a CT-based substudy of the SCALE Obesity trial (N=3,731) [19].

Testosterone Replacement Therapy (Men)

In hypogonadal men, testosterone replacement therapy (TRT) reduces VAT by improving insulin sensitivity and shifting fat distribution away from visceral depots. The T-TRIALS (N=790 men, testosterone <275 ng/dL) showed that testosterone gel (1%) applied daily for 12 months reduced VAT by a mean of 13 cm² on CT versus placebo [20]. TRT is not indicated for VAT reduction in eugonadal men.

Menopausal Hormone Therapy (Women)

Estradiol-based hormone therapy in recently menopausal women attenuates VAT accumulation. A randomized controlled trial published in the Journal of Clinical Endocrinology and Metabolism (N=93) found that transdermal estradiol 0.05 mg/day for 6 months reduced VAT area by 8.2 cm² compared to placebo (P<0.05) [21]. Benefits appear most pronounced when therapy starts within 10 years of menopause, aligning with the "timing hypothesis" supported by the Endocrine Society.

What Low VAT Means

Very low VAT is not a clinical concern for most people. A DEXA result below 100 cm² (or below 1.0 kg) indicates low visceral fat burden and is associated with favorable metabolic outcomes. There is no medical indication to increase VAT.

Lipodystrophy: A Rare Exception

In rare cases, extremely low VAT alongside low subcutaneous fat may indicate lipodystrophy, a condition of pathological fat loss. Congenital generalized lipodystrophy and familial partial lipodystrophy produce paradoxical metabolic syndrome despite near-absent body fat, because the liver and muscle store ectopic lipid in the absence of normal adipose depots. The Endocrine Society published clinical practice guidelines on lipodystrophy syndromes in 2016 [22]. Any adult with VAT below 20 cm² combined with severe insulin resistance, hypertriglyceridemia, and a lean phenotype warrants endocrinology referral.

Who Should Get VAT Measured?

Routine VAT measurement is not yet a standard-of-care screening test. Specific groups benefit from knowing their VAT:

• Adults with a BMI of 25 to 30 kg/m² who have unexplained dyslipidemia, prediabetes, or elevated CRP, since BMI underestimates visceral fat risk in this range.
• Adults considering GLP-1 therapy who want an objective baseline to track treatment response.
• Postmenopausal women and men over 50 with recent weight gain concentrated in the abdomen.
• Patients with known MASLD, metabolic syndrome, or polycystic ovary syndrome (PCOS), where VAT quantification guides treatment intensity.

The USPSTF recommends that clinicians offer or refer adults with a BMI of 30 or greater to intensive, multicomponent behavioral weight-loss interventions [23]. VAT measurement can identify adults below that BMI threshold who carry equivalent metabolic risk.

Tracking Progress: How Often to Retest

Most clinical protocols repeat DEXA-based body composition every 3 to 6 months during active intervention. VAT responds faster to lifestyle change than total body fat. A dedicated aerobic training program producing roughly 500 kcal/session of energy expenditure may reduce VAT by a measurable 5 to 10 cm² within 12 weeks. Pharmacologic therapy with semaglutide typically produces the largest VAT changes between weeks 16 and 40, reflecting its biphasic weight-loss curve.

Serial DEXA from the same machine and software version is preferred, as cross-platform differences in VAT algorithms can introduce 10 to 15% measurement variability.

A DEXA VAT result above 160 cm² at baseline that fails to drop below 130 cm² after 6 months of consistent lifestyle intervention warrants a conversation about pharmacologic options, including GLP-1 receptor agonist therapy, TRT in hypogonadal men, or MHT in eligible postmenopausal women.